Pharsight

Drugs that contain Oxybutynin Chloride

1. Ditropan Xl patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5840754 JANSSEN PHARMS Dosage form comprising oxybutynin
May, 2015

(8 years ago)

US6262115 JANSSEN PHARMS Method for the management of incontinence
May, 2015

(8 years ago)

US5674895 JANSSEN PHARMS Dosage form comprising oxybutynin
May, 2015

(8 years ago)

US5912268 JANSSEN PHARMS Dosage form and method for treating incontinence
May, 2015

(8 years ago)

US5912268

(Pediatric)

JANSSEN PHARMS Dosage form and method for treating incontinence
Nov, 2015

(8 years ago)

US6262115

(Pediatric)

JANSSEN PHARMS Method for the management of incontinence
Nov, 2015

(8 years ago)

US5840754

(Pediatric)

JANSSEN PHARMS Dosage form comprising oxybutynin
Nov, 2015

(8 years ago)

US5674895

(Pediatric)

JANSSEN PHARMS Dosage form comprising oxybutynin
Nov, 2015

(8 years ago)

Market Authorisation Date: 16 December, 1998

Treatment: Management of incontinence, mgt of hormone replacement therapy, treatment of involuntary incontinence, mgt overactive bladder and increasing compliance in such pt

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of DITROPAN XL before it's drug patent expiration?
More Information on Dosage

DITROPAN XL family patents

Family Patents

2. Gelnique patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10272061 ABBVIE Compositions and methods for unoccluded transdermal oxybutynin therapy
Apr, 2020

(3 years ago)

US7179483 ABBVIE Compositions and methods for transdermal oxybutynin therapy
Apr, 2020

(3 years ago)

US8241662 ABBVIE Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy
Apr, 2020

(3 years ago)

US7029694 ABBVIE Compositions and methods for transdermal oxybutynin therapy
Apr, 2020

(3 years ago)

US10449173 ABBVIE Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
Nov, 2029

(5 years from now)

US9259388 ABBVIE Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
Nov, 2029

(5 years from now)

US8920392 ABBVIE Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
Mar, 2031

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Jan 27, 2012

Market Authorisation Date: 27 January, 2009

Treatment: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency or urge incontinence; Treatment of patients with an overactive bladder with symptoms of urinary frequency, ...

Dosage: GEL;TRANSDERMAL

How can I launch a generic of GELNIQUE before it's drug patent expiration?
More Information on Dosage

GELNIQUE family patents

Family Patents